Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study

Journal of the European Academy of Dermatology and Venereology

Volumn 32, Issue 11, 2018, Pages 1940-1949

  Gordon, K B ^a   Armstrong, A W ^b   Han, C ^c   Foley, P ^d   Song, M ^c   Wasfi, Y ^c   You, Y ^c   Shen, Y K ^c   Reich, K ^e  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Dermatologikum Berlin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; GUSELKUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; POST HOC ANALYSIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT RESPONSE; ANXIETY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ADMINISTRATION; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL; ANXIETY; CROSS-OVER STUDIES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85050508740     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.15012     Document Type: Article

References (46)

1. Lamb RC, Matcham F, Turner MA et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol 2017; 176: 1028–1034.
2. Fleming P, Roubille C, Richer V et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2015; 29: 1063–1070.
3. Dowlatshahi EA, Wakkee M, Herings RM, Hollestein LM, Nijsten T. Increased antidepressant drug exposure in psoriasis patients: a longitudinal population-based cohort study. Acta Derm Venereol 2013; 93: 544–550.
4. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17–27.
5. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846–850.
6. Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989–1004.
7. Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011; 164(Suppl 1): 1–14.
8. Dalgard FJ, Gieler U, Tomas-Aragones L et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984–991.
9. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000; 14: 267–271.
10. Gooderham M, Gavino-Velasco J, Clifford C, MacPherson A, Krasnoshtein F, Papp K. A review of psoriasis, therapies, and suicide. J Cutan Med Surg 2016; 20: 293–303.
11. Kimball AB, Leonardi C, Stahle M et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014; 171: 137–147.
12. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891–895.
13. Wu JJ, Penfold RB, Primatesta P et al. The risk of depression, suicidal ideation, and suicide attempt in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Eur Acad Dermatol Venereol 2017; 31: 1168–1175.
14. Han C, Lofland JH, Zhao N, Schenkel B. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 2011; 10: 843–850.
15. Gordon KB, Duffin KC, Bissonnette R et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 2015; 373: 136–144.
16. Blauvelt A, Papp KA, Griffiths CEM et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405–417.
17. Reich K, Armstrong A, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418–431.
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.
19. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale with the Irritability Depression-Anxiety Scale and the Leeds Situational Anxiety Scale Manual. GL Assessment Ltd, London, UK, 1994.
20. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69–77.
21. Damen NL, Pelle AJ, Szabó BM, Pedersen SS. Symptoms of anxiety and cardiac hospitalizations at 12 months in patients with heart failure. J Gen Intern Med 2012; 27: 345–350.
22. Watson TM, Ford E, Worthington E, Lincoln NB. Validation of mood measures for people with multiple sclerosis. Int J MS Care 2014 Summer; 16: 105–109.
23. Hopwood P, Howell A, Maguire P. Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. Br J Cancer 1991; 64: 349–352.
24. Wojtyna E, Łakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezińska-Wcisło L. Gender, body image and social support: biopsychosocial determinants of depression among patients with psoriasis. Acta Derm Venereol 2017; 97: 91–97.
25. Wu Y, Mills D, Bala M. Impact of psoriasis on patients’ work and productivity: a retrospective, matched case-control analysis. Am J Clin Dermatol 2009; 10: 407–410.
26. Solovan C, Marcu M, Chiticariu E. Life satisfaction and beliefs about self and the world in patients with psoriasis: a brief assessment. Eur J Dermatol 2014; 24: 242–247.
27. Investing in treatment for depression and anxiety leads to fourfold return. 2016. URL http://www.who.int/mediacentre/news/releases/2016/depression-anxiety-treatment/en/ (last accessed: 21 August 2017).
28. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19: 397–403.
29. Langley RG, Feldman SR, Han C et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457–465.
30. Daudén E, Griffiths CEM, Ortonne JP et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374–1382.
31. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54: 685–704.
32. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29–35.
33. Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol 2017; 31: 798–807.
34. Turner J, Kelly B, Clarke D et al. A tiered multidisciplinary approach to the psychosocial care of adult cancer patients integrated into routine care: the PROMPT study (a cluster-randomised controlled trial). Support Care Cancer 2017; 25: 17–26.
35. Deterding K, Gruner N, Buggisch P et al. Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. Eur J Gastroenterol Hepatol 2016; 28: 187–192.
36. Gracie DJ, Williams CJM, Sood R et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol 2016; 111: 541–551.
37. Traki L, Rostom S, Tahiri L et al. Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab. Clin Rheumatol 2014; 33: 1055–1060.
38. Tee SI, Lim ZV, Theng CT, Chan KL, Giam YC. A prospective cross-sectional study of anxiety and depression in patients with psoriasis in Singapore. J Eur Acad Dermatol Venereol 2016; 30: 1159–1164.
39. Mrowietz U, Chouela EN, Mallbris L et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol 2015; 29: 1114–1120.
40. Martínez-García E, Arias-Santiago S, Valenzuela-Salas I, Garrido-Colmenero C, García-Mellado V, Buendía-Eisman A. Quality of life in persons living with psoriasis patients. J Am Acad Dermatol 2014; 71: 302–307.
41. Gniadecki R, Robertson D, Molta CT et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012; 26: 1436–1443.
42. Golden SH, Shah N, Naqibuddin M et al. The prevalence and specificity of depression diagnosis in a clinic-based population of adults with type 2 diabetes mellitus. Psychosomatics 2017; 58: 28–37.
43. Poole NA, Morgan JF. Validity and reliability of the Hospital Anxiety and Depression Scale in a hypertrophic cardiomyopathy clinic: the HADS in a cardiomyopathy population. Gen Hosp Psychiatry 2006; 28: 55–58.
44. Silverstone PH. Poor efficacy of the Hospital Anxiety and Depression Scale in the diagnosis of major depressive disorder in both medical and psychiatric patients. J Psychosom Res 1994; 38: 441–450.
45. OTEZLA [package insert]. Summit, NJ: Celgene Corporation; 2014–2017.
46. SILIQ [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2017.